News & Events

Press Releases
June 3, 2019
GeneCentric Therapeutics will present the first data on novel response signatures for metastatic, muscle invasive bladder cancer (MIBC) treatments by applying its proprietary, RNA-sequencing based predictive response signature and Cancer Subtyping Platform…
February 18, 2019
GeneCentric Therapeutics, Inc. collaborator Dr. Tracy Rose from the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC presented at the Genitourinary Cancers Symposium today on: “Fibroblast growth factor receptor status and response…
January 3, 2019
CEO Dr. Myla Lai-Goldman named Executive Chairperson Durham, NC, January 3, 2019 -GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Executive Officer and President and will…
December 10, 2018
Focus is on advancing cancer subtypes to predict disease progression and pursuing immune-biology related drug response biomarkers DURHAM, N.C., December 10, 2018 — GeneCentric Therapeutics, Inc. today announced that it has entered…
September 24, 2018
Company will develop Pancreatic Cancer Profiler based on technology to identify drug responders for therapeutic development DURHAM, N.C., September 24, 2018 — GeneCentric Therapeutics, Inc. today announced that the company has acquired…
September 10, 2018
GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Scientific Officer (CSO).  Dr. Milburn, who joins GeneCentric from Metabolon, Inc. where he was CSO, has more than…
August 17, 2018
GeneCentric Therapeutics’ CEO, Dr. Myla Lai-Goldman, will deliver a presentation at the Precision Medicine World Conference (PMWC) 2018 Duke University Program, September 24-25, entitled: “Delivering Greater Precision to Precision Medicine.” In an…
August 15, 2018
Dr. Myla Lai-Goldman, co-founder and CEO of GeneCentric Therapeutics, will co-Chair a panel at the Next Generation Diagnostics (Dx) Summit 2018, August 20-24 in Washington, DC titled: “Paths to Universal Drug-Diagnostics Co-Development.”…
May 30, 2018
GeneCentric Therapeutics announced today that it will present the first data on the application of its proprietary Cancer Subtyping Platform (CSP®) to bladder cancer and its potential utility to provide drug response biomarkers for the disease. The gene expression subtyping data will be presented in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL on June 2, 2018.
January 3, 2018
DURHAM, N.C., January 3, 2018 — GeneCentric Therapeutics, Inc. today announced a research collaboration to evaluate the potential of GeneCentric’s Cancer Subtype Platform (CSP®) to identify responders to G1 Therapeutics’ oral CDK4/6 inhibitor G1T38 for the treatment of non-small cell lung cancer (NSCLC).  As part of the research collaboration, GeneCentric will apply its lung cancer subtyping profilers (LSP™) in preclinical, patient-derived xenograft models to determine NSCLC subtype associations with G1T38 response, as well as examine potential drug response associations with specific genes.
Publications & Presentations
Events
No results found.